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ABSTRACT: Huntington disease (HD) is an inherited
neurodegenerative disease caused by the expansion beyond a
critical threshold of a polyglutamine (polyQ) tract near the N-
terminus of the huntingtin (htt) protein. Expanded polyQ
promotes the formation of a variety of oligomeric and fibrillar
aggregates of htt that accumulate into the hallmark proteina-
ceous inclusion bodies associated with HD. htt is also highly
associated with numerous cellular and subcellular membranes
that contain a variety of lipids. As lipid homeostasis and
metabolism abnormalities are observed in HD patients, we
investigated how varying both the sphingomyelin (SM) and
ganglioside (GM1) contents modifies the interactions between
htt and lipid membranes. SM composition is altered in HD,
and GM1 has been shown to have protective effects in animal
models of HD. A combination of Langmuir trough monolayer techniques, vesicle permeability and binding assays, and in situ
atomic force microscopy (AFM) were used to directly monitor the interaction of a model, synthetic htt peptide and a full-length
htt-exon1 recombinant protein with model membranes comprised of total brain lipid extract (TBLE) and varying amounts of
exogenously added SM or GM1. The addition of either SM or GM1 decreased htt insertion into the lipid monolayers. However,
TBLE vesicles with an increased SM content were more susceptible to htt-induced permeabilization, whereas GM1 had no effect
on permeablization. Pure TBLE bilayers and TBLE bilayers enriched with GM1 developed regions of roughened, granular
morphologies upon exposure to htt-exon1, but plateau-like domains with a smoother appearance formed in bilayers enriched
with SM. Oligomeric aggregates were observed on all bilayer systems regardless of induced morphology. Collectively, these
observations suggest that the lipid composition and its subsequent effects on membrane material properties strongly influence htt
binding and aggregation on lipid membranes.
■ INTRODUCTION
The expansion of a polyglutamine (polyQ) tract near the N-
terminus of the huntingtin (htt) protein is the primary cause of
Huntington’s disease (HD), a fatal neurodegenerative disor-
der.1 Expanded polyQ domains in htt are directly correlated
with a propensity to aggregate into a variety of proteinacious
structures ranging from small oligomers to fibrils.2−7 There is
also a strong correlation of the age of onset and disease severity
with the length of the polyQ domain, with ∼35 repeat
glutamines being the critical threshold required for the
disease.8−10 The exact mass of htt depends on the size of the
polyQ domain, but full-length htt is approximately 350 kDa and
3144 amino acids in size, based on a polyQ domain of 23. The
polyQ domain is contained within the 1st exon of htt and
begins at the 18th residue. htt undergoes a variety of cleavages
to produce a variety of N-terminal fragments comparable with
exon1,11,12 and numerous lines of evidence support the notion
that N-terminal fragments are directly involved in HD
pathogenesis.2,12−14
Several functions have been attributed to the htt protein,15
and many of these functions are directly related to interactions
between htt and lipid membrane interfaces.16−20 htt localizes to
specific subcellular surfaces21 and functions in the transport of
lipid vesicles (endocytic, synaptic, and lysosomal), especially
along microtubules.17−20 htt is also essential for the normal
development of several perinuclear membrane organelles,
including mitochondria and endoplasmic reticulum (ER).22,23
Furthermore, htt localizes with brain membrane fractions24 and
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intimately interacts with a variety of specific membrane lipid
components,25−29 including anionic phosphatidylinositol phos-
phates, consistent with an electrostatic-based mechanism for
membrane association.26−29 With regard to htt-exon1, the first
17 amino acids of htt (Nt17) directly preceding the polyQ tract
functions as a lipid-binding domain. Nt17 lipid-binding is
facilitated by the formation of highly conserved amphipathic α-
helix,21,30−32 and post-translational modifications of Nt17 can
alter the affinity of htt for lipid membranes.33
Beyond these normal functions of htt, there is increasing
evidence that lipid interactions may play a role in the toxic gain
of functions associated with the expansion of polyQ in htt, as
membrane-related changes (including mutant htt membrane
association and induced disruption as well as altered membrane
composition) are observed in HD.27,29,34−36 Whereas mutant
htt is primarily associated with the formation of microscopic
inclusion bodies in the cytoplasm and nucleus,13 about one-half
of the endogenous htt partitions with the membranes after
subcellular fractionation of neuronlike clonal striatal cells.25
Furthermore, htt associates with a variety of membranous
organelles, including mitochondria, ER, tubulovesicles, endo-
somes, lysosomes, and synaptic vesicles.37−39 Lipids are even
incorporated within htt aggregates observed in mouse models,
and the surface of htt inclusion bodies contain membranous
structural elements.24,40 A variety of amino-terminal mutant htt
fragments directly bind the lipid membranes, aggregate and
alter the mechanical properties of the membrane, and
ultimately cause membrane leakage in vitro.41−46 Perinuclear
inclusions of htt have been linked to disruption of the nuclear
envelope in HD mouse models,36 and expanded polyQ can
embed into ER, resulting in membrane distortion.47
Protein/lipid membrane interactions have been shown to
potentially play a role in a number of amyloid-related
diseases.43 Membrane composition may directly influence htt
aggregation and related toxicity. In this regard, there are a
variety of lipid homeostasis and metabolism abnormalities
associated with HD. Specifically, sphingomyelin (SM) fatty acid
composition in cerebral white matter is altered in both juvenile
and adult onset HD with an increase in short-chain fatty acids;
this finding has been attributed to disturbed myelination of
nerves.48,49 Metabolic profiling of presymptomatic HD in sheep
found a marked decrease in plasma sphingolipids, which may
reflect a disease signature,50 whereas an untargeted metab-
olomics approach in the STHdH cell line model of HD
identified altered sphingolipid metabolism.51 Furthermore,
reduced glycosphingolipid concentration is observed in
erythrocytes, striatum, and caudate in both HD patients and
animal models.52,53 Glycosphingolipid species play a number of
roles in maintaining neuronal viability, and in particular, GM1
has neuroprotective properties upon exposure to a variety of
toxic entities ranging from glutamate to amyloids.54,55 Reduced
levels of gangliosides may be related to the observed reduced
synthesis of GM1 in fibroblasts from HD patients as well as in
cell and animal models of HD.56 The expression of
glycosyltransferases is altered in HD, resulting in disrupted
glycolipid and ganglioside metabolic pathways in the caudate.53
GM1 deficiencies have been observed in the YAC128, R6/1,
and R6/2 transgenic mouse model of HD as well as in caudate
samples from human HD patients.53,56,57 Interestingly, the
GM1 content in the plasma membrane of HD cells correlated
with a cell’s susceptibility to apoptosis.56 Collectively, these
observations have led to a number of studies exploring the use
of GM1 as a potential therapeutic agent. For example, addition
of GM1 to the striatal cell line models of HD resulted in a
protective effect against htt toxicity, restoring cell survival to
wild-type levels.56 The additional GM1 activates AKT (Ser/
Thr-specific protein kinase), resulting in enhanced phosphor-
ylation of mutant htt,56 and phosphorylation is known to
reduce mutant-htt accumulation and induce toxicity.58−60 The
intraventricular infusion of GM1 in a symptomatic transgene
HD mouse model induced phosphorylation of residues 13 and
16 within Nt17 and attenuated htt toxicity, restoring normal
motor function.61 Beyond simply adding GM1, mitochondrial
modulators, alpha-lipoic acid and acetyle-L-carnitine, were able
to enhance glycosphingolipid levels in an experimental HD cell
model.62 Although the primary importance of htt aggregation in
HD has long been appreciated, the impact of specific lipid
components to modulating htt aggregation and its direct
interaction with membrane interfaces is poorly understood.
Here, we characterize the interaction of N-terminal htt
fragments with total brain lipid extract (TBLE) lipid
membranes that contain varying exogenous amounts of
sphingolipids, SM or GM1. The use of a variety of membrane
models [lipids monolayers at the air/buffer interface, large
unilamellar vesicles (LUVs), and supported lipid bilayers] and
biophysical techniques [in situ atomic force microscopy
(AFM), Langmuir trough techniques, and vesicle association/
permeability assays] enabled us to test a range of SM and GM1
concentrations, which can amplify any weak htt−sphingolipid
interaction to determine how varying the SM and GM1
concentrations affects the interactions of htt with lipid
membrane interfaces.
■ RESULTS AND DISCUSSION
Addition of SM or GM1 Modifies the Insertion of htt
into Lipid Membranes. To understand how the sphingoli-
pids, SM and GM1, with a common sphingosine backbone but
varying headgroups (SMphosphocholine; GM1complex
oligosaccharide) alter the interactions between htt and lipid
membranes, monomeric htt peptide (Nt17-Q35-P10-KK) in-
sertion into TBLE monolayers with varying amounts of
exogenously added SM or GM1 was measured using a
Langmuir trough (Figure 1). Upon injection to the subphase,
the peptide molecules partition between the bulk and air/buffer
interface because of the presence of the amphipathic N-
terminal lipid-binding domain, Nt17, until an equilibrium
spreading pressure is reached (Π = 17.3 mN/m at 900 nM
peptide42). Pure TBLE monolayers and those doped with 10 or
20 wt % exogenous SM or 5 or 10 wt % GM1 were spread at
the air/buffer interface and compressed to a physiologically
relevant surface pressure of 30 mN/m.63,64 The amounts of
exogenous SM and GM1 to be added were determined from
preliminary screening experiments that suggested the SM-
impacted htt/lipid interactions up to an addition of 20%,
whereas the impact of GM1 saturated after the 10% increase.
The exogenous amounts of SM and GM1 added to the TBLE
system are not physiological. Though TBLE with 10% GM1 or
30% SM will not be found within a cell membrane, these limits
were chosen to provide a clear experimental system to
determine how these lipid components interacted with htt.
The monolayers were held at this pressure as freshly prepared
monomeric peptide was injected into the subphase, and the
average area per molecule at the interface, an indication of
peptide insertion, was monitored until equilibrium was reached.
Then, the pressure was lowered 4 mN/m, and the process was
repeated. The addition of either SM or GM1 at any
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concentration decreased the extent of htt peptide insertion into
the monolayer at each surface pressure (Figure 1). These
decreases were statistically significant (p < 0.05) compared to
control using a t-test, except for addition of GM1 at surface
pressures greater than 26 mN/m and addition of SM at a
surface pressure of 26 mN/m. The reduced insertion scales
with the SM content; pure TBLE had a 28% total increase in
the area, whereas adding 10 wt % exogenous SM resulted in a
23% area increase and 20 wt % SM had an 18% increase.
However, the reduction in insertion associated with increased
GM1 concentration was similar for both 5 and 10 wt % used
here at ∼20% total increase in the area. Of note, regardless of
the amount of exogenous SM or GM1, Nt17-Q35-P10-KK
inserted into the lipid monolayers at surface pressures higher
than the previously measured equilibrium spreading pressure,
indicative of a driving force for the peptide to interact with the
TBLE membrane. This experiment measures htt peptide
association with and insertion into the lipid monolayer, as
determined by the headgroup chemistry and the lipid packing
density dictated by the phase state of the layer.
To ascertain how the addition of exogenous SM or GM1
affects TBLE membranes in decreasing the amount of htt
peptide insertion, individual surface pressure versus mean
molecular area isotherms were measured for the pure
components and a series of binary mixtures of TBLE with
SM or GM1 (Figure 2A,B). As pure TBLE and SM had similar
isotherms, an increase in the SM content did not dramatically
affect the TBLE monolayer isotherm. In terms of lipid mixtures,
the lipid raft hypothesis proposes that naturally occurring lipids
such as sphingolipids, glycosphingolipids, and cholesterol
specifically aggregate in the plane of the membrane driven
primarily by hydrogen bonding between the lipid headgroups
and alignment of saturated hydrocarbon chains.65 The SM
brain extract used here is a heterogonous mixture consisting of
SM molecules with a sphingosine backbone bound to one of a
variety of amide-linked fatty acids, of which the prominent ones
are stearic (C18:0, 50%) and lignoceric (C24:1, 21%) acids.
Adding this mixture of SM lipids to TBLE has a complex effect.
Because of the hydrogen-bonding capabilities in the sphingo-
sine backbone, neighboring headgroups can be tightly bound
and locally ordered.66 The SM molecules containing saturated
hydrocarbon fatty acid chains contribute to this close packing,
but the lignoceric acid has a cis-double bond in the chain that
promotes disorder and fluidity, resulting in a film with a
packing density (on average) similar to that of TBLE. The
decreased amount of htt insertion, as measured by an increase
in the monolayer area at a constant surface pressure in Figure 1,
that scales with the SM content suggests that the solidifying
effect of the increased hydrogen-bonding network in the lipid
headgroup region may prevent the physical insertion of Nt17.
By contrast, the TBLE/GM1 isotherms clearly demonstrate
TBLE monolayer condensation upon addition of GM1, relative
to ideal mixing (Figure 2B) where the inclusion of negatively
charged bulky oligosaccharide headgroups did not appreciably
change the area per molecule at a specific pressure. Comparison
of the mean molecular area of the binary mixtures to that of a
theoretical mean area consistent with ideal mixing of the TBLE
with GM1 suggests that exogenous GM1 causes condensation
or stiffening of the monolayer. This is in agreement with both
the lipid raft hypothesis, where ordered regions of the
membrane are enriched in gangliosides, and the GM1-induced
lateral condensation of lipids seen in binary DPPC/GM1
membranes.67 The GM1 condensation effect can be explained
by the electrostatic interactions between the headgroups,
alignment of dipole moments within their headgroups, and
the tendency of gangliosides to have cooperative interactions
qualitatively attributed to hydrogen bond formation between
adjacent sugar residues.68,69 Our interpretation is that the small
condensation effect seen at low GM1 concentrations
dramatically decreases the amount of htt peptide insertion
that leads to membrane lateral expansion.
SM and GM1 Alter the Susceptibility of Vesicles to
htt-Induced Permeability. Although lipid monolayers are a
convenient model for the outer leaflet of a cell membrane, it
should be noted that in addition to in-plane interactions
between monolayer components, cross-leaflet interactions
between the lipids in bilayer membranes also affect lipid
packing, and these effects are not captured in a monolayer
model,70 prompting the need for lipid bilayer assays to
Figure 1. Insertion of Nt17-Q35-P10-KK into lipid monolayers of
varying (A) TBLE/SM and (B) TBLE/GM1 ratios at the air/buffer
interface, expressed as % insertion at each surface pressure. The error
bars represent the standard deviation (n = 3 separate experiments).
Figure 2. Monolayer compression isotherms of (A) pure TBLE, pure
SM, and binary mixtures of TBLE and SM and (B) pure TBLE, pure
GM1, and binary mixtures of TBLE and GM1, measured at 30 °C.
Average area per molecule was calculated assuming an average TBLE
molecular weight of 850 g/mol.
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complement the measurements. As we have shown previously,
Nt17-Q35-P10-KK peptides permeablize TBLE vesicles, allowing
content leakage.42,45 To determine if altering the SM or GM1
content of TBLE bilayers changed the membrane susceptibility
to permeabilization by the htt peptide, calcein dye leakage
assays with LUVs were performed. Disruption of the LUV
membrane by external agents via mechanisms ranging from
short-lived pore formation to complete vesicle lysis results in
calcein release, dilution, and increased fluorescence emission
from the unquenched dye, allowing permeabilization to be
correlated with the fluorescence intensity. Solutions of
predominately monomeric Nt17-Q35-P10-KK were mixed with
vesicles comprised of TBLE containing varying amounts of
exogenously added SM or GM1, and maximum fluorescence
signal was measured (Figure 3). Measurements were taken after
3 min of exposure to the peptide, as both our previous studies
on related systems42,45 and our current work indicate that the
peptide interacts with membranes to induce the maximal
amount of leakage, and hence the fluorescence, within this
timeframe. Nt17-Q35-P10-KK induced a significant calcein
release from LUVs comprised of pure TBLE, that is,
approximately 30% increase in relative fluorescence at the
highest peptide concentrations compared to 0.7% arising from
control volumes of trifluoroacetic acid (TFA)/phosphate-
buffered saline (PBS) buffer (Figure 3). As the SM content
of the LUVs was increased, the extent of calcein dye leakage
induced by exposure to Nt17-Q35-P10-KK drastically increased,
with maximum leakage at the highest SM levels (Figure 3A).
Just 5% addition by mass of SM to TBLE LUVs significantly
increased permeabilization at all peptide concentrations, except
at a peptide concentration of 0.484 μM (based on t-tests, p ≤
0.02), and the addition of 30 wt % SM approximately doubled
the permeabilization. All increases in calcein dye leakage
associated with SM content greater than 5% were statistically
significant (based on t-tests, p ≤ 0.02). Increased susceptibility
of SM containing LUVs to Nt17-Q35-P10-KK-induced perme-
abilization was unexpected based on the decreased amount of
peptide insertion into TBLE monolayers enriched in SM, as
measured on a Langmuir trough. This suggests that SM
increases the efficiency of lipid-bound htt to induce membrane
permeabilization, such that a lower concentration of mem-
brane-inserted htt resulted in greater content leakage. This may
be attributed to the disruption of the sphingosine H-bonding
network, which could increase leakage for comparable amounts
of peptide insertion. By contrast, decreased insertion of htt into
membranes containing exogenous GM1, as measured by
Langmuir isotherms, did not correlate with a significant change
in membrane permeabilization of LUVs based on t-tests (Figure
3B).
Enriching TBLE with SM or GM1 Alters the Extent of
htt-Exon1 Binding to Lipid Vesicles, as Determined by a
TBLE/PDA Binding Assay. To verify that enhancing the lipid
content of TBLE with SM or GM1 would modulate the
interaction of a larger fragment of htt, full-length htt-exon1,
with lipids, we performed a TBLE/PDA vesicle lipid-binding
assay (Figure 4). This assay uses mixed vesicles comprised of
Figure 3. Calcein leakage, measured as relative fluorescence, from
LUVs composed of different (A) TBLE/SM ratios or (B) TBLE/GM1
ratios, exposed to Nt17-Q35-P10-KK (or buffer acting as a control) as a
function of the peptide concentration. The error bars indicate one
standard deviation (n = 3 separate experiments).
Figure 4. Percent colorimetric response (% CR) of TBLE/
polydiacetylene (PDA) vesicles containing various amounts of
exogenous (A) SM or (B) GM1 upon exposure to htt-exon1(51Q)
plotted as a function of time. The error bars indicate 1 standard
deviation (n = 3).
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phospholipids and polymerized PDA, which appear blue
because of absorbance λmax ≈ 640 nm. Upon interaction with
an exogenous particle or macromolecule, the PDA side-chain
groups in the vesicle can become disordered, leading to an
irreversible distortion of the side chains that strains the polymer
backbone. This disruption leads to a change in the effective
conjugated length of the PDA bonds, resulting in a rapid, visible
color change to red.71,72 The colorimetric response can be used
to quantify peptide/membrane interactions and interfacial
membrane processes such as protein aggregation that would
cause structural perturbations of the lipid interface. PDA-based
vesicles have been used to study a variety of protein/lipid
interactions, including those involving amyloid proteins.73−75
The TBLE/PDA vesicles were systematically prepared with
different ratios of lipid components. These included pure
TBLE, TBLE enriched with 10, 20, or 30% SM by mass, and
TBLE enriched with 5, 10, or 15% GM1 by mass. These
different vesicle preparations were exposed to freshly prepared
htt-exon1(51Q) at a concentration of 20 μM, and % CR was
measured for 16 h (Figure 4). Typically, an initial steady
increase in % CR is observed upon exposure of TBLE/PDA
vesicles to htt-exon1(51Q), and the % CR eventually reaches a
quasi-steady state. As the exogenous SM content was enriched
from 0 to 10%, the interaction of htt-exon1(51Q) with the
vesicles was significantly reduced (p ≤ 0.02 at each time point,
based on a t-test). However, an increase in the SM content
resulted in enhanced htt/lipid interaction (p ≤ 0.02 at each
time point based on a t-test). The interactions between htt and
vesicles enriched with 20 or 30% SM were indistinguishable.
The enhanced % CR associated with the addition of SM at 20%
or higher is consistent with the increased leakage measured by
the calcein dye assay, suggesting that the PDA assay detects an
induced change in the membrane associated with disruption. In
comparison with the calcein dye leakage assay, the reduced %
CR associated with the addition of 10% SM suggests that SM
enhances the susceptibility of membranes to htt-induced
damage. Though less htt peptide is physically inserted, leading
to reduced lateral expansion in the SM-doped TBLE
membrane, the associated htt disrupts and permeabilizes the
membrane more effectively. A small 5% increase in GM1 to the
vesicles modestly decreased the htt/lipid interaction at early
time points. Increasing the GM1 content by 10 or 15%
dramatically inhibited the interaction of htt-exon1(51Q) with
the lipid vesicles (p ≤ 0.02 at each time point based on a t-test),
which was consistent with the previous measurements of
decreased peptide insertion into the lipid monolayer.
SM and GM1 Modulate the Morphological Changes in
Lipid Bilayers Associated with Exposure to htt. We
investigated the influence of SM or GM1 on the aggregation of
htt on lipid membranes using in-solution AFM. Supported lipid
bilayers on mica were systematically produced with varying
lipid contents. These lipid bilayers included pure TBLE, TBLE
+ 10 wt % SM, TBLE + 20 wt % SM, TBLE + 5 wt % GM1,
and TBLE + 10 wt % GM1. Such supported lipid bilayers are
known to retain several important properties associated with
lipid membranes, such as lateral fluidity,76 and similar systems
have been used as model surfaces to study protein aggregation
with lipid membranes.33,41−43,45,77−82 Pure TBLE bilayers and
those with exogenously added SM or GM1 were all smooth in
appearance [root mean square (rms) roughness less than 0.2
nm], with no indication of distinct micron-scale lipid domains
or phase separation prior to exposure to htt-exon1(51Q)
(Figure 5A), and were stable with no induced morphological
changes for at least 8 h under continuous AFM imaging. Having
Figure 5. (A) AFM height images taken in-solution of continuous, supported lipid bilayers of TBLE, TBLE + 10% SM, TBLE + 20% SM, TBLE +
5% GM1, and TBLE + 10% GM1 prior to exposure to any htt-exon1(51Q). (B) Sequential AFM height images taken in-solution of supported TBLE
bilayers exposed to htt-exon1(51Q). Blue rectangles identify the same region of the surface in the sequential images. (C) Zoomed-in AFM images
demonstrating the rough, grainy morphological changes induced in a pure TBLE bilayer by htt-exon1(51Q). Blue arrows indicate oligomeric
aggregates. (D) Height and volume histograms of oligomeric aggregates observed on TBLE bilayers presented as a function of time. To ease
visualization, the histograms were normalized for each time point by setting the value of the most common height or volume to 1.
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established that supported bilayers appropriate for this study
could be made from the different lipid mixtures, these model
bilayers were systematically exposed to freshly prepared
aliquots of htt-exon1(51Q) at a final protein concentration of
20 μM in the AFM fluid cell and continuously imaged using
AFM in-solution, allowing for the direct tracking of protein
aggregation on the bilayer. Only continuous TBLE bilayers (40
× 40 μm in size), as assessed by AFM imaging, were exposed to
htt-exon1(51Q), and observations were limited to these verified
regions of the continuous bilayer.
Consistent with our previous studies,45 pure TBLE bilayers
exposed to 20 μM solutions of htt-exon1(51Q) quickly (within
1 h) develop regions characterized by extensive roughness (rms
roughness greater than 1.0 nm) and appearance of discrete,
oligomeric htt aggregates (Figure 5B). These regions of
increased roughness expand in area and become increasingly
rougher with time (observed for up to 5 h). Previous reports
have correlated these morphological changes with altered
mechanical properties of the lipid bilayer and membrane
leakage.42,45,46 Although the number of oligomers observed on
the surface increased with time, these oligomers appeared to be
stable (Figure 5C,D). That is, specific individual oligomers
could be identified in subsequent images without large changes
in their size. As a population, the average size of oligomers did
not change with time (a mode of 4−5 nm in height and ∼22
000 nm3 in volume that was uncorrected for the size of the
AFM probe) (Figure 5D). Collectively, these observations
suggest that the TBLE bilayer promotes and stabilizes these
specific oligomeric species. htt fibrils were not observed on lipid
bilayers during the time course of the experiment. The same
htt-exon1(51Q) construct has been shown to readily form
fibrils over the same time course under the same preparation
conditions and concentration in the absence of lipids.83 The
lack of fibril formation on the pure TBLE bilayer suggests that
the lipid system either promotes the formation of aggregates off
the pathway to fibrils or that aggregate intermediate oligomers
are stabilized by interaction with the membrane.
When TBLE bilayers were enriched with 10 or 20% SM, the
morphological changes associated with exposure to htt-
exon1(51Q) were altered (Figure 6A,B). When TBLE was
enriched with 10% SM, the regions of the bilayer altered were
smaller in area and had a smoother, plateau-like appearance.
These regions increased in height with time. These regions
were also not associated with the abundant formation of
oligomeric aggregates. With the addition of 20% SM to TBLE
bilayers, regions of increased roughness that were associated
with the appearance of small oligomers initially developed;
however, the morphology of these regions evolved with time to
eventually form plateau-like domains that extended 10−16 nm
above the surface, corresponding to the height of several lipid
bilayers. These plateau-like domains are clearly distinguishable
in phase-contrast AFM imaging, suggesting that they are
mechanically different than the unaffected regions of the bilayer
(Figure 6C). Fewer htt oligomers were observed on bilayers
Figure 6. (A) Sequential AFM height images taken in-solution of supported TBLE bilayers enriched with either 10 or 20% SM exposed to htt-
exon1(51Q). Blue rectangles identify the same region of the surface in the sequential images. (B) Zoomed-in AFM images demonstrating the
morphological changes induced in TBLE bilayers enriched in SM. Blue arrows indicate oligomeric aggregates. Green lines correspond to the height
profiles presented directly below the images. The lower right corners of the images for the 1 h time point are presented at the same height scale as
the 3 h images for easier comparison. (C) AFM image split into height and phase data of a region of a TBLE + 20% SM bilayer exposed to htt-
exon1(51Q). (D) Height and volume histograms of oligomeric aggregates observed on TBLE bilayers enriched with 20% SM, presented as a
function of time. To ease visualization, the histograms were normalized for each time point by setting the value of the most common height or
volume to 1.
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that contained 20% exogenous SM compared with pure TBLE.
Oligomers observed on bilayers with the 20% extra SM were
initially slightly smaller (a mode of 2−3 nm in height and ∼20
000 nm3 in uncorrected volume) than the stable oligomers
associated with aggregation of htt on pure TBLE bilayers
(Figure 6D). After 2 h, the oligomers observed on lipid bilayers
with 20% SM increased in size, but were still slightly smaller
than those observed on pure TBLE.
When TBLE bilayers were enriched with 5 or 10% GM1, the
resulting morphological change associated with exposure to htt-
exon1(51Q) was similar to that observed on pure TBLE
bilayers; however, the area of the bilayer altered decreased with
increasing GM1 content (Figure 7A,B) parallel to the lipid
monolayer insertion and TBLE/PDA binding assays, which
indicated decreased htt insertion/association at a higher GM1
concentration. Patches of increased bilayer roughness that were
highly associated with the appearance of htt oligomers
developed, but these areas developed more slowly with
increasing GM1 content. The number of oligomers increased
with time on bilayers with both 5 or 10% enrichment with
GM1, and these oligomers were morphologically indistinguish-
able from those observed in pure TBLE bilayers (a mode of 4−
5 nm in height and ∼22 000 nm3 in uncorrected volume;
Figure 7B,C). The oligomers were also stable as individual
oligomers could be observed in subsequent images for several
hours, and their dimensions did not appreciably change. After 5
h of exposure to htt-exon1(51Q), some fibrils could be
observed in one trial with TBLE + 5% GM1 (Figure 7A).
To quantify the interaction of htt-exon1(51Q) with the
supported bilayers containing various amounts of SM or GM1
as observed by AFM, the percentage of the surface that
displayed any altered morphology and the rms roughness of
those regions were determined as a function of time via image
analysis (Figure 8). Despite the differences in the developed
morphology associated with exposure to htt-exon1(51Q), with
the addition of 10% SM, the percent area of the total bilayer
altered was smaller compared with that observed with pure
TBLE bilayers; but the addition of 20% SM resulted in an
increased area of the bilayer with an altered morphology. This
relative area of altered morphology observed by AFM was
consistent with our PDA assay, which measures interfacial
disruption induced by htt-exon1(51Q). With the addition of
GM1, there was no significant change in the area of the bilayer
surface displaying altered morphology until enrichment with
10% GM1, when the modified surface area was lessened, and
Figure 7. (A) Sequential AFM height images taken in-solution of supported TBLE bilayers enriched with either 5 or 10% GM1 exposed to htt-
exon1(51Q). Blue rectangles identify the same region of the surface in the sequential images. Black arrows indicate fibrillar aggregates. (B) Zoomed-
in AFM images demonstrating the rough, grainy morphological changes induced in TBLE bilayers enriched in GM1. Blue arrows indicate oligomeric
aggregates. (C) Height and volume histograms of oligomeric aggregates observed on TBLE bilayers enriched with GM1 presented as a function of
time. To ease visualization, the histograms were normalized for each time point by setting the value of the most common height or volume to 1.
ACS Omega Article
DOI: 10.1021/acsomega.7b01472
ACS Omega 2018, 3, 273−285
279
there was no significant change in the rms roughness of these
regions compared with the pure TBLE controls.
Role of htt/Lipid Interactions in HD Pathogenesis. The
interaction of htt with membranous surfaces may mediate
pathogenesis in several ways. These include the direct
promotion or stabilization of specific aggregate species,42
compromised mechanical integrity of cellular and subcelluar
membranes,36,41,44,46,47 and altered trafficking of htt within the
cell.21 Several lines of evidence point to a prominent toxic role
for oligomeric species,84−86 and lipids may promote the
formation and stability of specific oligomeric species. Such a
scenario is consistent with our direct observation of stable
oligomers that formed on the various bilayers studied here and
previous reports indicating that synthetic polyQ peptides
aggregate differently on bilayer surfaces compared with mica
substrates.42 If specific htt conformations or aggregates play a
pivotal role in HD, understanding how specific lipid
components may shift the relative abundance of disease
relevant conformations may be critical. Although enriching
TBLE bilayers with GM1 reduced the total insertion of the
peptide into lipid monolayers and the accumulation of htt on
lipid bilayers, it did not result in a significant reduction of
membrane permeabilization in our study, suggesting that
reduced susceptibility of membranes to htt-induced disruption
may not contribute to the protective effect associated with
GM1 replacement in HD models. As GM1 modulates the
action of numerous cellular receptors, GM1 deficits associated
with HD interrupt the processes associated with these receptors
that can be rescued by restoring GM1 levels. In addition, GM1
treatments were found to enhance htt phosphorylation in mice,
which is known to reduce htt-related toxicity.56,61
Previously, we reported that enriching TBLE bilayers with
cholesterol resulted in large plateau-like domains upon
exposure to htt-exon1(51Q) of the bilayer, similar to those
seen in SM-doped membranes; however, these cholesterol-
enriched membranes were resistant to htt-induced permeabi-
lization in contrast to SM-enriched ones.45 One key difference
between these two systems is that the plateau-like regions that
developed in the bilayers enriched with SM grew to be thicker
and mechanically different (based on phase imaging) compared
to the unaffected regions of the bilayer. In the case of
membranes enriched with cholesterol, oligomeric aggregates of
htt were not observed to form on the membrane surface at any
time to an appreciable extent.45 With this in mind, it is
interesting to note that enrichment with SM (of at least 20%)
and GM1 here resulted in htt-induced membrane permeabiliza-
tion (Figure 3) to a similar or greater extent compared with
pure TBLE bilayers and that oligomers (although sometimes
transient) were observed under all of these conditions (Figures
5−7). Collectively, these observations suggest that the
formation of oligomers may play a key role in the ability of
htt to induce membrane permeabilization. These findings also
justify the need for the analysis of how the altered membrane
composition affects the htt peptide structure upon binding.
■ CONCLUSIONS
Lipid interactions are associated with a number of wild-type
functions attributed to htt. Membrane damage and altered lipid
homeostasis are the biochemical features of HD, and this htt-
induced damage to membranes represents a potential toxic
mechanism in HD, as a similar membrane disruption has been
associated with a number of other amyloid-forming proteins. As
a result, determining the factors that regulate the affinity of htt
for membranes is critical not only for understanding the normal
functions of htt but also for identifying ways to modify htt−
lipid interactions for potential therapeutic strategies. In this
study, we investigated the role of sphingolipids, SM and GM1,
in modulating the interaction with and subsequent aggregation
of model htt peptides (both synthetic and recombinant) on
TBLE lipid membranes and the associated consequences. The
exogenous addition of SM or GM1 to TBLE lipid monolayers
reduced the insertion of htt, likely due to the increased extent
of the sphingosine backbone hydrogen-bonding network within
the membrane. The extent of htt-induced vesicle permeabiliza-
tion was not affected by the addition of GM1, whereas
increasing the SM content enhanced the susceptibility of
Figure 8. Percent area of disrupted bilayer morphology and increased rms roughness associated with exposure of lipid bilayers containing various
amounts of (A,B) SM or (C,D) GM1 to htt-exon1(51Q), presented as a function of time. The error bars indicate 1 standard deviation over three
separate experiments.
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vesicles to htt-induced permeability; though less htt was
inserted into the membranes containing a higher concentration
of sphingolipid, the disruption induced by htt caused more
content leakage. In agreement with the lipid monolayer
insertion experiments, the total interaction of htt with bilayers
enriched with GM1 was reduced, as measured by both a
colorimetric assay and AFM. Although the extent of bilayer
alteration caused by exposure to htt was reduced with
increasing GM1 content, the actual morphological features
associated with the affected regions of the bilayer, including
oligomer formation, were consistent with those observed on
pure TBLE. The extent of htt/lipid interaction varied greatly
with the SM content, and the induced morphological changes
of the bilayer were distinct in comparison with those observed
on pure TBLE bilayers. These observations suggest that
sphingolipid composition strongly influences the material
properties of the lipid membrane, which affects htt binding
and aggregation, and that subsequent oligomer formation on
the interface may correlate with membrane permeabilization.
■ METHODS
Peptide Preparation. A synthetic, model htt peptide
consisting of the Nt17 domain, 35 glutamines (sufficient for
aggregation),87 a polyproline (polyP) domain 10 residues in
length, and 2 C-terminal lysines, referred to as Nt17-Q35-P10-
KK, was obtained via custom synthesis (Keck Biotechnology
Resource Laboratory, New Haven, Connecticut). Lysines were
added to enhance solubility. Established protocols for
disaggregation and solubilization of the peptide were used.88
In short, the peptide was dissolved overnight in a 1:1 mixture of
TFA (Acros Organics) and hexafluoroisopropanol (Acros
Organics) at 0.5 mg/mL. A stream of N2 was used to evaporate
the solvent, and the residual solvent was removed using a
Vacufuge concentrator for 3 h (Eppendorf, Hauppauge, NY).
The resulting peptide films, stored at −20 °C, were then
dissolved in ultrapure water adjusted to pH 3 with TFA at a
concentration of 200 μM. This solution was subsequently
diluted in PBS (10 mM phosphate, 140 mM NaCl, 2.7 mM
KCl) (Life Technologies) to a final concentration of 20 μM
and a final pH of 7.3.
Purification of Glutathione S-transferase (GST)−htt-
Exon1 Fusion Proteins. GST−htt-exon1 fusion proteins
containing 51 repeat glutamines were purified, as previously
described.89 Briefly, the GST−htt fusion proteins were
expressed by induction in Escherichia coli with isopropyl β-D-
thiogalactoside at 30 °C for 4 h, and the cells were lysed with
lysozyme (0.5 mg/mL). Fusion proteins were purified from the
lysate with a GST affinity column via liquid chromatography
(LPLC, BioRad). Relevant fractions were identified by
ultraviolet absorption and confirmed by gel electrophoresis.
Before use in any assay, the solutions of fusion proteins were
centrifuged at 20 000g for 30 min at 4 °C to remove preexisting
aggregates. GST was cleaved by Factor Xa (Promega, Madison,
WI), and this cleavage initiates aggregation. Experiments were
carried out in buffer A (50 mM Tris-HCl, pH 7.0, 150 mM
NaCl). To ensure efficient GST cleavage, the GST−htt-exon1
fusion protein and the respective cleavage agents were
incubated for 1 h on ice prior to their addition to any assay.
Langmuir Trough Configuration. All lipid monolayer
surface pressure versus molecular area isotherms and peptide
insertion experiments were performed in a Teflon Langmuir
trough with symmetric barriers (large inverted microscopy
model, NIMA Technologies, Coventry, England). A stationary
Wilmhelmy balance (NIMA Technologies, Coventry, England)
was used to measure the surface pressure at the air/buffer
interface. All measurements were collected at 30 ± 0.5 °C, and
the trough temperature was maintained with a circulating
heated water bath (Isotemp 3016D water circulator, Thermo
Fisher Scientific).
Lateral Compression Experiments. Lipid monolayer
isotherms were conducted to characterize monolayer phase
behavior as a function of lipid-packing density and membrane
composition. Stock TBLE (Avanti Polar Lipids) (extract lipid
headgroup composition: 9.6 wt % phosphatidylcholine, 16.7 wt
% phosphatidylethanolamine, 1.6 wt % phosphatidylinositol,
10.6 wt % phosphatidylserine, 2.8 wt % phosphatidic acid, and
58.7 wt % unknown) was obtained in chloroform and used
without further purification. Because of the uncharacterized
composition of TBLE, an average TBLE molecular weight of
850 g/mol was assumed. SM (brain, porcine; Avanti Polar
Lipids) was received in powder form and was dissolved in
chloroform (Sigma-Aldrich). In the SM brain extract, the
amide-linked fatty acid bound to the sphingosine backbone
varies with the following composition: C16:0 2%, C18:0 50%,
C20:0 5%, C22:0 7%, C24:0 5%, C24:1 21%, and others 10%.
GM1 ganglioside (brain, ovine, sodium salt; Avanti Polar
Lipids) was received in powdered form and dissolved in 8:2
chloroform/methanol. TBLE was mixed in different ratios with
SM or GM1 to a total spreading concentration of 0.4 mg/mL
and stored in glass vials at −20 °C. The lipid monolayer was
formed by dropwise addition of the spreading solution on the
PBS (pH = 7.3) surface; the solvent was allowed to evaporate
for 15 min. Barriers compressed the monolayer at 6 cm2/min,
and isotherm measurements in the form of surface pressure
(mN/m) versus mean area per lipid molecule (Å2/molecule)
were taken at 1 s intervals until monolayer collapse.
Measuring Peptide Insertion into a Lipid Monolayer.
Insertion experiments were performed to quantify the Nt17-Q35-
P10-KK peptide insertion into pure TBLE and mixed TBLE/SM
and TBLE/GM1 monolayers. The lipid monolayer was
compressed to a surface pressure of 30 mN/m to match the
lateral density of a cellular bilayer,63,64 and then, the barriers
were switched to feedback mode to maintain a constant surface
pressure by adjusting the monolayer surface area. Lyophilized
peptide was rehydrated in TFA/PBS, as described above, and
immediately injected beneath the compressed monolayer to
obtain a 900 nM final peptide concentration in the subphase.
After 10 min, if no increase in the average area per molecule to
signify peptide insertion was observed, the maintained surface
pressure was reduced 4 mN/m and the process was repeated
down to a minimum of 14 mN/m. Percent insertion of the
peptide at each surface pressure was determined as a % increase
in the area [(Afinal − Ainit)/Ainit × 100].
Vesicle Preparation for Leakage Assay. LUVs of TBLE,
TBLE/SM, and TBLE/GM1 were prepared to determine
internal content leakage caused by htt peptide insertion. Lipid
films, evaporated from stock solution with a stream of N2, were
hydrated in 70 mM calcein (Sigma) in 10 mM Tris, pH = 7.3
via 5 min of vortexing and 5 min of sonication. The vesicles
were treated with 7 freeze−thaw cycles in ethanol/dry ice and
warm water baths and then extruded 11 times through a 100
nm-pore polycarbonate filter (Avanti). The excess dye was
removed with size exclusion chromatography using Sephadex
G-50 beads (Sigma-Aldrich). Vesicle diameter size uniformity
(120−160 nm depending on vesicle composition) was
confirmed with dynamic light scattering [Zetasizer ZS90
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(Malvern Worcestershire, UK)]. Lipid concentration was
determined by a phosphorus assay adapted from Anderson
and Rouser.90,91 Briefly, a lipid fraction (500 μL) and 8.9 N
H2SO4 (225 μL) were vortexed and heated at 210 °C for 20
min. After cooling, 6% H2O2 (75 μL) was added and heated for
an additional 25 min at 210 °C until the solution was colorless.
After cooling, 1.95 mL of ultrapure water, 5% molybdic acid
(225 μL), and 10% ascorbic acid (225 μL) were added, and the
solution was placed in a boiling water bath for 10 min.
Absorbance at 820 nm was measured using a Jasco V-550 UV/
visible spectrophotometer (Jasco, Easton, MD) and compared
to a KH2PO4 reference plot to calculate the final lipid
concentration.
Vesicle Leakage Assay. TBLE LUVs with exogenous SM
(0−30 wt %) or GM1 (0−15 wt %) were exposed to the Nt17-
Q35-P10-KK peptide in a concentration range, resulting in
peptide/lipid molar ratios ranging from 1:67 to 1:1.7 at 25 °C.
Lyophilized peptides were hydrated as outlined above and used
promptly to minimize the presence of nonmonomeric species.
Fluorescence at 515 nm (495 nm excitation) from calcein was
measured prior to peptide exposure and 3 min after peptide
administration using a RF-1501 spectrofluorometer (Shimadzu,
Columbia, MD). Vesicles were then completely lysed using 1%
Triton X-100 (Sigma) to measure the maximum calcein
fluorescence. Vesicle leakage caused by the peptide was
calculated by
= −
−
×I I
I I
% relative fluorescence 100f I
T I (1)
where If is the fluorescent intensity after peptide addition, II is
the initial fluorescence of the LUVs, and IT is the total
fluorescence intensity after complete lysis.
TBLE/PDA Lipid-Binding Assay. TBLE/PDA assays were
performed using previously reported protocols.75,92 In sum-
mary, diacetylene monomers 10,12-tricosadiynoic acid (GFS
Chemicals, Columbus, OH), TBLE, and an appropriate amount
of either SM or GM1 were dissolved in a solution of 1:1
chloroform/ethanol. Total lipid and PDA was always mixed in a
2:3 molar ratio. The solution was evaporated off in a rotary
evaporator. The resulting films were resuspended in Tris-
buffered saline, heated to 70 °C, sonicated for 5 min at 100 W
using a sonic dismembrator (FisherSci), and stored at 4 °C
overnight to ensure self-assembly of the vesicles. Polymer-
ization of the diacetylene monomers was accomplished by
irradiation at 254 nm with 7 lumens for 10 min (room
temperature with stirring), which results in a blue color.
Polymerized TBLE/PDA vesicles were exposed to htt-exon1-
(51Q) at a final concentration of 20 μM. TBLE/PDA vesicle
samples were also exposed to 1× buffer A (negative control) or
NaOH (pH 12) (positive control). All experiments were
performed in triplicate in a 96-well format, and the colorimetric
response at 500 and 640 nm was recorded for 16 h with an
Infinite M1000 Pro plate reader (TECAN, Switzerland) at 25
°C. A quantitative value representative of the blue-to-red color
transition was obtained by determining the % CR, defined
as75,92
= − ×% CR [(PB PB )/PB ] 1000 I 0 (2)
where PB is the red/blue ratio of absorbance (A) defined as
Ablue/(Ablue + Ared). Ablue is the absorbance at ∼640 nm
(absorbance at this wavelength range results in a blue color),
Ared is the absorbance at ∼500 nm, PB0 is the red/blue ratio of
the control sample (before induction of color change), and PBI
is the value obtained for the vesicle solution after addition of
peptides.
AFM Imaging Conditions. In-solution AFM experiments
were performed with a Nanoscope V MultiMode scanning
probe microscope (Bruker, Santa Barbara, CA) equipped with a
closed-loop “vertical engage” J-scanner and a sealed tapping
fluid cell. Images were acquired with silicon cantilevers
(VISTAprobes) with spring constants of ∼0.1 N/m, scan
rates of ∼2 Hz, and drive frequencies ranging from ∼8 to 10
kHz. AFM images were processed and analyzed using
MATLAB and its image processing toolbox (Mathworks,
Natick, MA), as previously described.83
Preparation of Supported Bilayers for AFM Experi-
ments. TBLE, SM, and GM1 (Avanti Polar Lipids) were
dissolved in chloroform (Fisher Scientific) and mixed at
appropriate ratios to have samples of pure TBLE and TBLE
spiked with specific weight percentages of exogenously added
SM or GM1. The chloroform was evaporated off using a
Vacufuge concentrator (Eppendorf, Hauppauge, NY). The
resulting lipid films were resuspended in buffer A (pH 7.3) at
0.5 mg/mL. To form vesicles, these lipid suspensions
underwent five sequential freeze−thaw cycles, followed by 15
min of sonication in a bath sonicator. The resulting vesicle
solutions (35 μL) were injected into the AFM fluid cell. The
formation of a continuous bilayer on mica via vesicle fusion was
observed by continual AFM imaging, and all AFM experiments
were performed between 23 and 25 °C. The fluid cell was
flushed to remove vesicles remaining in solution. htt-exon1-
(51Q) was then injected into the cell to a final concentration of
20 μM, and the protein was present for the entirety of the
experiment.
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